Drugs could mimic gut bacteria benefits to treat diabetesIt may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat Share XDrugs could mimic gut bacteria benefits to treat diabeteshttps://pharmaphorum.com/news/drugs-gut-bacteria-diabetes/
J&J’s Invokana reduces risk of renal failure in high-risk diabetes patientsJohnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the Share XJ&J’s Invokana reduces risk of renal failure in high-risk diabetes patientshttps://pharmaphorum.com/news/jjs-invokana-reduces-risk-of-renal-failure-in-high-risk-diabetes-patients/
PBM cuts insulin co-pay as lawmaker confrontations loomExpress Scripts has announced a plan to cut patient co-pays for insulin products at $25 a month ahead Share XPBM cuts insulin co-pay as lawmaker confrontations loomhttps://pharmaphorum.com/news/pbm-insulin-express-scripts/
NICE backs funding for MSD’s diabetes drug SteglatroNICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro Share XNICE backs funding for MSD’s diabetes drug Steglatrohttps://pharmaphorum.com/news/nice-backs-funding-for-msds-diabetes-drug-steglatro/
AZ’s diabetes drug Forxiga approved in EU for type 1 diseaseAstraZeneca’s diabetes drug Forxiga (dapagliflozin) has been approved in the EU in patients with type 1 disease. Forxiga Share XAZ’s diabetes drug Forxiga approved in EU for type 1 diseasehttps://pharmaphorum.com/news/azs-diabetes-drug-forxiga-approved-in-eu/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Lilly to sell generic Humalog insulin at half priceEli Lilly has responded to criticism of high prices for insulin products in the US by launching a Share XLilly to sell generic Humalog insulin at half pricehttps://pharmaphorum.com/news/lilly-to-sell-generic-humalog-insulin-at-half-price/
CHMP okays Sanofi’s Zynquista in type 1 diabetesSanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a Share XCHMP okays Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/chmp-okays-sanofis-zynquista-in-type-1-diabetes/
Rani completes first trial of capsule that could replace injectionsResults of the first human study of a capsule designed to replace injections of biologics have been announced, Share XRani completes first trial of capsule that could replace injectionshttps://pharmaphorum.com/news/rani-completes-first-trial-of-capsule-that-could-replace-injections/
